Plain-English translation of NCT04664179 on ClinicalTrials.gov ↗ ·
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new treatment called C7R-EBV T cells for people with lymphoma caused by Epstein-Barr virus (EBV). Researchers take your own immune cells, add a new gene to them using a harmless virus carrier, and then give them back to you to fight the cancer. The goal is to see if these modified cells can help control or shrink your lymphoma.
Many people with EBV-positive lymphoma don't respond well to standard treatments or their cancer comes back. This medication is designed to harness your body's own immune system to specifically target and destroy lymphoma cells infected with EBV, offering a new option for patients who need it most.
You likely qualify if…
You likely don't qualify if…
First, you'll donate blood so researchers can grow and modify your immune cells, a process that takes several weeks. When the cells are ready, you may receive chemotherapy for 3 days to prepare your body, then receive an infusion of your modified cells through an IV line (taking 1–10 minutes). You'll stay in Houston for up to 2 weeks for close monitoring, then return for follow-up visits at weeks 1, 2, 4, and 6, then at months 3, 6, 9, and 12, and yearly for 15 years total to watch for any long-term effects from the gene modification.
AI-generated summary from trial data · Aug 5, 2026 · Not medical advice
United States